Axumin PET Scans: A Breakthrough for Prostate Cancer

Axumin is an FDA-approved, Medicare-covered scan that can achieve early detection of recurrent prostate cancer after surgery or radiation. For years we have been able to detect prostate cancer recurrences with PSA, but standard body and bone scans have been unable to determine the location of the cancer until the PSA level is excessively elevated (10 to 30 or higher).

Axumin can detect recurrent disease with PSA levels less than 10 and sometimes much lower, which is the reason this scan is such an important development. READ THE FULL ARTICLE HERE >

3 thoughts on “Axumin PET Scans: A Breakthrough for Prostate Cancer

    • Prostate Oncology Post authorReply

      Indication: Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. You may find a list of facilities here:

Leave a Reply

Your email address will not be published. Required fields are marked *